Hantz Financial Services, Inc. Cytokinetics Inc Transaction History
Hantz Financial Services, Inc.
- $6.19 Billion
- Q2 2025
A detailed history of Hantz Financial Services, Inc. transactions in Cytokinetics Inc stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 1,308 shares of CYTK stock, worth $78,702. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,308
Previous 44
2872.73%
Holding current value
$78,702
Previous $2,000
2050.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CYTK
# of Institutions
371Shares Held
129MCall Options Held
3.62MPut Options Held
1.14M-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$1.06 Billion0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$883 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$721 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$471 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$383 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.66B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...